Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9487478B2 · kind B2 · utility
4Cited by
16References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 1, 2015 |
| Grant date | Nov 8, 2016 |
| Priority date | — |
| Expiry date | Oct 1, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2430/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are compounds of formula (I)and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.